|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Vemurafenib改善伴BRAF V600E突变的黑色素瘤患者的生存率显示文摘背景 BRAF激酶抑制剂vemurafenib(PLX4032)的1期和2期临床试验已证实其对伴BRAFV600E突变的转移性黑色素瘤患者的反应率超过50%。方法我们在675例既往未经治疗、伴BRAFV600E突变的转移性黑色素瘤患者中,实施了一项Ⅲ期随机化临床试验以比较vemurafenib和Dacarbazine(氮烯唑胺)。患者通过随机分配,分别接受vemurafenib(每次口服960mg,每天两次)或氮烯唑胺(每3周静脉注射1000mg·m-2体表面积)。本研究主要终点是比较总体生存率及无进展期生存率。次要终点包括反应率、反应持续时间以及安全性。计划在死亡98例患者时进行中期分析、死亡196例时进行最终分析。结果在治疗6个月后,vemurafenib组总体生存率为84%(95%置信区间[CI],78-89),而氮烯唑胺组为64%(95%CI,56-73)。在对总体生存率的中期分析及无进展期生存率的最终分析中,与氮烯唑胺相比,vemurafenib能相对减低63%的死亡风险,以及减低74%的死亡或者疾病进展风险(两种比较P<0.001)。通过数据及安全监督委员会进行独立中期分析审查后,建议氮烯唑胺组患者也转而服用vemurafenib。对Vemurafenib反应率是48%而氮烯唑胺只有5%。伴Vemurafenib常见不良反应为关节痛、皮疹、疲劳、脱发、角化棘皮瘤或鳞状细胞癌、光过敏、恶心和腹泻;38%的患者因为毒副作用要求调整剂量。结论 Vemurafenib能改善既往未经治疗、伴有BRAFV600E突变的黑色素瘤患者的总体及无进展期生存率。(本研究由瑞士罗氏制药有限公司资助;BRIM-3临床试验编号:NCT01006980) | 涂超 Chapman PB Hauschild A Robert C | 2011 | 肿瘤药学2011，1，5： | 2 |
| 2 | Elevated IL-6 levels in the synovial fluid of osteoarthritis patients stem from plasma cells 显示文摘 | Doss F Menard J Hauschild M | 2007 | Scand J Rheumatol2007，36，2： | 1 |
| 3 | Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage Ⅳ melanoma 显示文摘 | Middleton M Hauschild A Thomson D | 2007 | Ann Oncol2007，18，10： | 1 |
| 4 | Improved survival with vemurafenib in melanoma with BRAF V600E mutation 显示文摘 | Chapman PB Hauschild A Robert C | 2011 | N Engl J Med2011，364，： | 1 |
| 5 | Life cycle assessment of disposal of residues from municipal solid waste incineration: Recycling of bottom ash in road construction or landfilling in Denmark evaluated in the ROAD-RES model显示文摘 | H. Birgisdóttir G. Bhander M.Z. Hauschild T.H. Christensen | 2007 | Waste Management2007，，8： | 1 |
| 6 | Polarized Neutron Reflectometry Study of Thin Fe Films Prepared on V(100) 显示文摘 | Liu Y T Fritzshe H Hauschild J | 2004 | PhysicaB2004，350，： | 1 |
| 7 | Kalman-Filter-based GPS Clock Estimation for Near Real-Time Positioning 显示文摘 | Hauschild A Montenbruck O | 2009 | GPS Solutions2009，13，3： | 1 |
| 8 | Initial As- sessment of the COMPASS/BeiDou-2 Regional Navigation Satel- lite System 显示文摘 | Montenbruck O Hauschild A Steigenberger P | 2013 | GPS Solutions2013，17，2： | 1 |
| 9 | Improved survival with vemurafenib in melanoma with BRAF V600E mutation 显示文摘 | Chapman PB Hauschild A Robert C | 2011 | N Engl J Med2011，364，26： | 1 |
| 10 | ZnO rediscovered-Once again!?显示文摘 | C Klingshirn R Hauschild H Priller | 2006 | Advances in Spectroscopy for Lasers and Sensing2006，231，： | 1 |
| 11 | Dabrafenib in BRAF -mutated metastatic melanoma : a multicentre, open- label, phase 3 randomised controlled trial显示文摘 | Hauschild A Grob JJ Demidov LV | 2012 | Lancet2012，380，9839： | 1 |
| 12 | Orbit and clock analysis of compass GEO and IGSO satellites显示文摘 | STEIGENBERGER P HUGENTOBLER U HAUSCHILD A | 2013 | Journal of Geodesy2013，87，6： | 1 |
| 13 | Predictive value of serum SlOOp for monitoring patients with metastatic melanoma during chemotherapy adn/or immunotherapy 显示文摘 | Hauschild A Engel G Brenner W | 2003 | Br J Demratol2003，11，： | 1 |
| 14 | Identification of risk factors for neurnlogical deficits in patients with pelvic freclures显示文摘 | Schmal H Hauschild O CuIemann U | 2010 | Orthopedics2010，33，8： | 1 |
| 15 | Improved survival with vemurafenib in melanoma with BRAF V600E mutation显示文摘 | CHAPMAN P B HAUSCHILD A ROBERT C | | 0，，26： | 1 |
| 16 | ZnO rediscovered-once again! ?显示文摘 | Klingshim C Hauschild R Priller H | 2005 | Superlattices and Microstructures2005，38，： | 1 |
| 17 | Results of a phase Ⅲ, randomized, placebo-controlled study of so- rafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage Ⅲ or stage Ⅳ melanoma 显示文摘 | Hauschild A Agarwala SS Trefzer U | 2009 | J Clin Oncol2009，27，17： | 1 |
| 18 | Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E-mutated melanoma:An update from the Phase Ⅲ randomized,open-label,multicenter BRIM3 trial显示文摘 | HAUSCHILD A MCARTHUR G A ROBERT C | | 0，，： | 1 |
| 19 | Improved sur-viral with vemurafenib in melanoma with BRAF V600E muta- tion 显示文摘 | Chapman PB Hauschild A Robert C | 2011 | N Engl j Med2011，364，26： | 1 |
| 20 | Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease显示文摘 | Margaret McCusker Nicole Basset-Seguin Reinhard Dummer Karl Lewis Dirk Schadendorf Aleksandar Sekulic Jeannie Hou Lisa Wang Huibin Yue Axel Hauschild | 2013 | European Journal of Cancer2013，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员